Publications by authors named "Alessandro D Santin"

Claim this Profile
T
The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201.
Susana N Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian, Véronique D'Hondt, Bradley J Monk, Alessandro D Santin

Future Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.
Susana N Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian, Véronique D'Hondt, Bradley J Monk, Alessandro D Santin

J Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunohistochemistry, next generation sequencing (NGS), and whole exome sequencing concordance in HER2 testing in uterine serous carcinoma: a retrospective analysis.
Victoria M Ettorre, Stefania Bellone, Natalia Buza, Pei Hui, Tobias Max Philipp Hartwich, Alessandro D Santin

Gynecol Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Folate receptor alpha as a successful biomarker in the treatment of low-grade serous ovarian cancer patients using preclinical and clinical models.
Victoria M Ettorre, Beatrice Conca, Cem Demirkiran, Stefania Bellone, Namrata Sethi, Alessandro D Santin

Int J Gynecol Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effective preclinical activity of datopotamab deruxtecan (Dato-DXd), an ADC targeting trophoblast cell-surface antigen 2 (TROP2), against primary cervical carcinoma cell lines and xenografts.
Victoria M Ettorre, Cem Demirkiran, Stefania Bellone, Tobias Max Philipp Hartwich, Michelle Greenman, Alessandro D Santin

Gynecol Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful Sequential Use of the Antibody-Drug Conjugate Trastuzumab Deruxtecan After Progression on Sacituzumab Govitecan in a Recurrent Treatment-Resistant Ovarian Cancer Patient: A Case Report.
Victoria M Ettorre, Michelle Greenman, Luca Palmieri, Cem Demirkiran, Alessandro D Santin

Cureus· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The VEGF/VEGFR2 system in ovarian cancer: From functional to pharmacological significance.
Elisabetta Grillo, Chiara Romani, Victoria M Ettorre, Alessandro D Santin, Stefania Mitola

Biochim Biophys Acta Rev Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Co-expression of tissue factor, TROP2, and NECTIN4 in primary and matched metastatic cervical cancer lesions.
Marit L Ulvang, Oda Fløtre Kvile, Hege F Berg, Kathrine Woie, Ingfrid S Haldorsen, Alessandro D Santin

Transl Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.
Susana N Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian, Véronique D'Hondt, Bradley J Monk, Alessandro D Santin

J Clin Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical activity of sacituzumab govitecan in TROP2-positive low-grade serous ovarian cancer patient-derived xenograft models.
Victoria M Ettorre, Cem Demirkiran, Stefania Bellone, Na Niu, Natalia Buza, Alessandro D Santin

Int J Gynecol Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody-Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas.
Niccolò G Santin, Namrata Sethi, Stefania Bellone, Cem Demirkiran, Victoria M Ettorre, Alessandro D Santin

Cancer Res Commun· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor.
Cem Demirkiran, Stefania Bellone, Victoria M Ettorre, Miranda Mansolf, Tobias Max Philipp Hartwich, Niccoló G Santin, Alessandro D Santin

Int J Mol Sci· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Datopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcoma.
Michelle Greenman, Stefania Bellone, Cem Demirkiran, Tobias Max Philipp Hartwich, Victoria M Ettorre, Niccolo G Santin, Alessandro D Santin

Gynecol Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2/neu as a Signaling and Therapeutic Marker in Uterine Serous Carcinoma.
Victoria M Ettorre, Luca Palmieri, Valentino Clemente, Alessandro D Santin

Cells· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical pharmacologic considerations for antibody-drug conjugate in gynecologic cancers.
Victoria M Ettorre, Luca Palmieri, Alessandro D Santin

Expert Rev Clin Pharmacol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analyses.
Victoria M Ettorre, Stefania Bellone, Michelle Greenman, Blair McNamara, Luca Palmieri, Alessandro D Santin

Gynecol Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Activity of Datopotamab Deruxtecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma.
Michelle Greenman, Cem Demirkiran, Stefania Bellone, Tobias M P Hartwich, Blair McNamara, Niccolo G Santin, Alessandro D Santin

Cancer Res Commun· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Personalized Treatment in Ovarian Cancer: A Review of Disease Monitoring, Biomarker Expression, and Targeted Treatments for Advanced, Recurrent Ovarian Cancers.
Victoria M Ettorre, Abdelrahman AlAshqar, Namrata Sethi, Alessandro D Santin

Cancers (Basel)· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma.
Daniela E Matei, Danielle M Enserro, Marcus E Randall, David Mutch, William Small, Alessandro D Santin

J Clin Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-acetylcysteine (NAC) supplementation improves dyspnea and may normalize von Willebrand plasma levels in gynecologic patients with Post-Acute-COVID-Sequela (PASC)/Long COVID.
Stefania Bellone, Eric R Siegel, Alessandro D Santin

Gynecol Oncol Rep· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utility of next generation sequencing to unequivocally establish clonality in synchronous vs metastatic endometrial and ovarian carcinomas.
Michelle Greenman, Stefania Bellone, Tobias Hartwich, Natalia Buza, Alessandro D Santin

Gynecol Oncol Rep· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unmet needs in cervical cancer - can biological therapies plug the gap?
Michelle Greenman, Yifan Emily Chang, Blair McNamara, Levent Mutlu, Alessandro D Santin

Expert Opin Biol Ther· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical evaluation of avutometinib and defactinib in high-grade endometrioid endometrial cancer.
Tobias Max Philipp Hartwich, Miranda Mansolf, Cem Demirkiran, Michelle Greenman, Stefania Bellone, Alessandro D Santin

Cancer Med· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sacituzumab govitecan in heavily pretreated, platinum-resistant high grade serous ovarian cancer.
Michelle Greenman, Stefania Bellone, Cem Demirkiran, Tobias Max Philipp Hartwich, Alessandro D Santin

Gynecol Oncol Rep· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses.
Dana M Roque, Eric R Siegel, Natalia Buza, Stefania Bellone, Gloria S Huang, Alessandro D Santin

BJC Rep· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis